The media database brings together all published information on platforms and products, as well as financial and corporate news.
Join our mailing list.
06/18/2024
ADOCIA Announces Three Presentations at the American Diabetes Association 84th Scientific Sessions

Interview Olivier Soula – La France de Demain, Radio Classique – May 2024 (FR)
Olivier Soula – LSX World Congress – April 2024
04/24/2024
ADOCIA Announces Full Year 2023 Financial Results and Provides a Corporate and Financial Update

Interview Olivier Soula – Le Journal des Biotechs – March 2024 (FR)
03/21/2024
ADOCIA Announces a €2 Million Fundraising from its two Main Shareholders and a Member of its Management, and the Signature of an Equity Financing Line with Vester Finance

BIO-Europe Spring 2024: Interview with Jérémy Benattar
Web-conference – 4th Quarter 2023 Financial Results (FR)
01/17/2024
ADOCIA Announces Half year report on Adocia’s liquidity agreement with Kepler Capital Markets

Olivier Soula – Le Revenu TV – Dec. 2023 (FR)
Web conférence – Diabète : un laboratoire pour le futur de la santé – déc. 2023 (FR)
Olivier Soula – Investival Showcase
11/09/2023
ADOCIA Revealed Promising Preclinical Data on AdoShell® Islets for Cell Therapy of Diabetes

10/25/2023
ADOCIA Reports Financial Results of Third Quarter 2023 and Provides an Update on its Activities

10/23/2023
ADOCIA’s Partner Tonghua Dongbao Announces Positive Results of Three Clinical Trials on BioChaperone® Combo

Jérémy Benattar – Investisseur.TV (FR)
Olivier Soula – Bourse et Valeurs, Lyon Pole Bourse (FR)
09/25/2023
ADOCIA Announces Oral Presentations on AdoShell® Islets at EASD and IPITA-IXA-CTRMS Congresses

09/13/2023
ADOCIA Announces the Availability of a Prospectus for the Admission to Trading of Shares Issued or likely to be Issued to IPF Partners on Exercise of its Warrants

08/31/2023
ADOCIA Announces that it has Received €500.000 in Proceeds from a Partial Exercise of Warrants Held by IPF Partners

07/31/2023
ADOCIA Announces Half year report on Adocia’s liquidity agreement with Kepler Capital Markets

Join our mailing list. Subscribe